Suit filed in India to close Ranbaxy plants, probe company

06/10/2013 | BioSpectrum Asia

Following a $500 million settlement with the US FDA over selling adulterated drugs, the generic-drug firm Ranbaxy Laboratories is facing a public-interest lawsuit in India to shutter the two Indian manufacturing plants involved in the FDA settlement and launch a companywide investigation. The lawsuit alleges "outright fraud, in which the company knowingly sold substandard drugs around the world." Ranbaxy disputed the allegations, stating that all of its products are safe and effective.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA